8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 18, 2026·SEC
Material company update
Jan 12, 2026·SEC
USANA Health Sciences, Inc.(USNA)Earnings, Financials & Key Ratios
USNA•NYSE
32.6× P/E·Price updated Jun 19, 2026
AboutUSANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.Show more
- Revenue$925M+8.3%
- EBITDA$91M+2.3%
- Net Income$11M-74.4%
- EPS (Diluted)0.58-73.5%
- Gross Margin78.29%-1.4%
- EBITDA Margin9.79%-5.5%
- Operating Margin5.5%-29.2%
- Net Margin1.16%-76.4%
- ROE1.84%-76.3%
USNA Key Insights
USANA Health Sciences, Inc. (USNA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong Piotroski F-Score: 7/9
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 3.1% through buybacks
- ✓Trading at only 0.6x book value
- ✓Efficient asset utilization: 1.2x turnover
✗Weaknesses
- ✗Profits declining 38.7% over 5 years
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when USNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
USNA Price & Volume
USANA Health Sciences, Inc. (USNA) stock price & volume — 10-year historical chart
Loading chart...
USNA Growth Metrics
USANA Health Sciences, Inc. (USNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years0.07%
5 Years-4%
3 Years-2.51%
TTM8.28%
Profit CAGR
10 Years-19.54%
5 Years-38.73%
3 Years-46.27%
TTM-74.42%
EPS CAGR
10 Years-16.66%
5 Years-37.03%
3 Years-45.54%
TTM-74.75%
Return on Capital
10 Years31.07%
5 Years20.48%
3 Years13.13%
Last Year8.32%
USNA Recent Earnings
USANA Health Sciences, Inc. (USNA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.61+38.6%
$0.44
Rev
$250M+3.7%
$241M
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$0.60+46.3%
$0.41
Rev
$226M+0.1%
$226M
Q4 2025
Oct 21, 2025Metric
Actual
Est
EPS
$0.15-160.0%
$0.25
Rev
$214M-2.8%
$220M
Q3 2025
Jul 22, 2025Metric
Actual
Est
EPS
$0.74+37.0%
$0.54
Rev
$236M+4.4%
$226M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.61vs $0.44+38.6% | $250Mvs $241M+3.7% |
| Q1 2026 | Feb 17, 2026 | $0.60vs $0.41+46.3% | $226Mvs $226M+0.1% |
| Q4 2025 | Oct 21, 2025 | $0.15vs $0.25-160.0% | $214Mvs $220M-2.8% |
| Q3 2025 | Jul 22, 2025 | $0.74vs $0.54+37.0% | $236Mvs $226M+4.4% |
Based on last 12 quarters of dataView full earnings history →
USNA Peer Comparison
USANA Health Sciences, Inc. (USNA) competitors in Nutrition and functional foods — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NUS | 243.72M | 5.02 | 1.58 | -14.26% | 3.78% | 6.84% | 0.45 | |
 NATR | 353.81M | 20.12 | 18.98 | 5.67% | 4.06% | 12.08% | 0.12 | |
 NHTC | 20.31M | 1.82 | -23.73 | -7.42% | -3.03% | -4.88% | 0.13 | |
 HLF | 1.23B | 11.90 | 5.41 | 0.89% | 4.67% | |||
 PLBY | 135.38M | 1.45 | -11.15 | 4.13% | -6.21% | -79.7% | 10.81 | |
 ATGE | 3.7B | 106.64 | 17.57 | 12.85% | 13.41% | 18.37% | 0.54 | |
 MGPI | 351.34M | 16.44 | -3.29 | -23.77% | -45.97% | -32.05% | 0.37 | |
 VITL | 446.05M | 10.41 | 7.23 | 25.26% | 6.1% | 14.47% | 0.15 |
Compare USNA vs Peers
USANA Health Sciences, Inc. (USNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
USNA Income Statement
USANA Health Sciences, Inc. (USNA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Jan'26 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.05B | 1.19B | 1.06B | 1.13B | 1.19B | 998.6M | 921.01M | 854.5M | 925.26M |
Revenue Growth % | 4.09% | 13.56% | -10.79% | 6.95% | 4.57% | -15.83% | -7.77% | -7.22% | 8.28% |
Cost of Goods Sold | 195.36M | 217.44M | 202.03M | 222.86M | 230.93M | 207.28M | 189.4M | 175.75M | 200.85M |
COGS % of Revenue | 18.65% | 18.28% | 19.04% | 19.64% | 19.46% | 20.76% | 20.56% | 20.57% | 21.71% |
Gross Profit | 851.9M▲ 0% | 971.81M▲ 14.1% | 858.87M▼ 11.6% | 911.79M▲ 6.2% | 955.53M▲ 4.8% | 791.32M▼ 17.2% | 731.62M▼ 7.5% | 678.75M▼ 7.2% | 724.4M▲ 6.7% |
Gross Margin % | 81.35% | 81.72% | 80.96% | 80.36% | 80.54% | 79.24% | 79.44% | 79.43% | 78.29% |
Gross Profit Growth % | 4.86% | 14.08% | -11.62% | 6.16% | 4.8% | -17.19% | -7.54% | -7.23% | 6.73% |
Operating Expenses | 719.4M | 783.46M | 712.68M | 735.29M | 785.34M | 683.7M | 638.54M | 612.43M | 673.54M |
OpEx % of Revenue | 68.69% | 65.88% | 67.18% | 64.8% | 66.19% | 68.47% | 69.33% | 71.67% | 72.8% |
Selling, General & Admin | 710.45M | 773.22M | 702.42M | 724.66M | 774.23M | 672.14M | 627.1M | 600.86M | 337.37M |
SG&A % of Revenue | 67.84% | 65.02% | 66.21% | 63.87% | 65.25% | 67.31% | 68.09% | 70.32% | 36.46% |
Research & Development | 8.95M | 10.24M | 10.26M | 10.63M | 11.11M | 11.56M | 11.45M | 11.57M | 0 |
R&D % of Revenue | 0.85% | 0.86% | 0.97% | 0.94% | 0.94% | 1.16% | 1.24% | 1.35% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 336.17M |
Operating Income | 132.5M▲ 0% | 188.35M▲ 42.1% | 146.19M▼ 22.4% | 176.49M▲ 20.7% | 170.19M▼ 3.6% | 107.61M▼ 36.8% | 93.07M▼ 13.5% | 66.32M▼ 28.7% | 50.86M▼ 23.3% |
Operating Margin % | 12.65% | 15.84% | 13.78% | 15.55% | 14.34% | 10.78% | 10.11% | 7.76% | 5.5% |
Operating Income Growth % | -4.41% | 42.15% | -22.39% | 20.73% | -3.57% | -36.77% | -13.51% | -28.74% | -23.31% |
EBITDA | 148.46M | 205.08M | 168.98M | 199M | 192.38M | 129.02M | 113.47M | 88.55M | 90.56M |
EBITDA Margin % | 14.18% | 17.24% | 15.93% | 17.54% | 16.21% | 12.92% | 12.32% | 10.36% | 9.79% |
EBITDA Growth % | -2.39% | 38.13% | -17.6% | 17.76% | -3.32% | -32.93% | -12.06% | -21.96% | 2.27% |
D&A (Non-Cash Add-back) | 15.96M | 16.73M | 22.79M | 22.51M | 22.19M | 21.41M | 20.39M | 22.23M | 39.7M |
EBIT | 134.69M | 191.55M | 146.19M | 178.46M | 170.7M | 108.81M | 102.72M | 76.63M | 42.37M |
Net Interest Income | 2.14M | 4.39M | 4.64M | 2.03M | 2.46M | 3.6M | 9.38M | 11.04M | 1.57M |
Interest Income | 2.19M | 4.43M | 4.71M | 2.54M | 2.52M | 3.79M | 9.64M | 11.32M | 2.42M |
Interest Expense | 46K | 36K | 66K | 507K | 57K | 192K | 262K | 281K | 842K |
Other Income/Expense | 2.14M | 3.16M | 4.31M | 1.46M | 450K | 1.01M | 9.38M | 10.03M | -9.34M |
Pretax Income | 134.64M▲ 0% | 191.51M▲ 42.2% | 150.5M▼ 21.4% | 177.95M▲ 18.2% | 170.64M▼ 4.1% | 108.62M▼ 36.3% | 102.45M▼ 5.7% | 76.35M▼ 25.5% | 41.53M▼ 45.6% |
Pretax Margin % | 12.86% | 16.1% | 14.19% | 15.68% | 14.38% | 10.88% | 11.12% | 8.94% | 4.49% |
Income Tax | 72.11M | 65.29M | 49.97M | 53.28M | 54.14M | 39.27M | 38.66M | 34.29M | 30.05M |
Effective Tax Rate % | 53.55% | 34.09% | 33.2% | 29.94% | 31.73% | 36.15% | 37.74% | 44.91% | 72.36% |
Net Income | 62.53M▲ 0% | 126.22M▲ 101.8% | 100.53M▼ 20.4% | 124.66M▲ 24.0% | 116.5M▼ 6.5% | 69.35M▼ 40.5% | 63.79M▼ 8.0% | 42.03M▼ 34.1% | 10.76M▼ 74.4% |
Net Margin % | 5.97% | 10.61% | 9.48% | 10.99% | 9.82% | 6.94% | 6.93% | 4.92% | 1.16% |
Net Income Growth % | -37.49% | 101.85% | -20.36% | 24.01% | -6.54% | -40.47% | -8.02% | -34.11% | -74.4% |
Net Income (Continuing) | 62.53M | 126.22M | 100.53M | 124.66M | 116.5M | 69.35M | 63.79M | 42.06M | 11.48M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 54.22M | 53.17M |
EPS (Diluted) | 2.53▲ 0% | 5.12▲ 102.4% | 4.41▼ 13.9% | 5.86▲ 32.9% | 5.73▼ 2.2% | 3.59▼ 37.3% | 3.30▼ 8.1% | 2.19▼ 33.6% | 0.58▼ 73.5% |
EPS Growth % | -36.59% | 102.37% | -13.87% | 32.88% | -2.22% | -37.35% | -8.08% | -33.64% | -73.52% |
EPS (Basic) | 2.60 | 5.36 | 4.44 | 5.89 | 5.78 | 3.60 | 3.33 | 2.20 | 0.58 |
Diluted Shares Outstanding | 24.71M | 24.64M | 22.82M | 21.26M | 20.34M | 19.31M | 19.34M | 19.16M | 18.57M |
Basic Shares Outstanding | 24.02M | 23.57M | 22.64M | 21.04M | 20.15M | 19.25M | 19.25M | 19.06M | 18.57M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
USNA Balance Sheet
USANA Health Sciences, Inc. (USNA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Jan'26 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 340.16M | 392.33M | 327.61M | 423.21M | 362.85M | 381.23M | 417.75M | 279.19M | 288.4M |
Cash & Short-Term Investments | 247.13M | 277.87M | 234.83M | 312.88M | 239.83M | 288.42M | 330.42M | 181.77M | 158.38M |
Cash Only | 247.13M | 214.33M | 234.83M | 312.88M | 239.83M | 288.42M | 330.42M | 181.77M | 158.38M |
Short-Term Investments | 0 | 63.54M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 13.46M | 14.03M | 8.76M | 7.42M | 7.16M | 7.21M | 7.2M | 8.22M | 0 |
Days Sales Outstanding | 4.69 | 4.31 | 3.01 | 2.39 | 2.2 | 2.64 | 2.85 | 3.51 | - |
Inventory | 62.92M | 81.95M | 68.91M | 90.22M | 98.32M | 67.09M | 61.45M | 69.73M | 102.61M |
Days Inventory Outstanding | 117.55 | 137.56 | 124.49 | 147.77 | 155.4 | 118.14 | 118.43 | 144.83 | 186.47 |
Other Current Assets | 8.34M | 9.2M | 4.95M | 4.01M | 3.68M | 7.12M | 7.28M | 5.7M | 27.42M |
Total Non-Current Assets | 179.11M | 162.13M | 189.33M | 217.68M | 214.89M | 215.32M | 215.01M | 469.01M | 454.51M |
Property, Plant & Equipment | 102.85M | 92.03M | 126.5M | 128.39M | 125.57M | 117.77M | 99.81M | 94.56M | 94.38M |
Fixed Asset Turnover | 10.18x | 12.92x | 8.39x | 8.84x | 9.45x | 8.48x | 9.23x | 9.04x | 9.80x |
Goodwill | 17.42M | 16.82M | 16.64M | 17.37M | 17.67M | 17.37M | 17.1M | 144.17M | 137.96M |
Intangible Assets | 35.15M | 31.81M | 29.84M | 30.8M | 30.44M | 32.43M | 29.92M | 151.82M | 133.15M |
Long-Term Investments | 9.81M | 2.91M | 2.86M | 3.06M | 23.82M | 2.9M | 2.83M | 2.74M | 0 |
Other Non-Current Assets | 11.02M | 15.22M | 10.41M | 33.42M | 12.55M | 35.05M | 52.07M | 56.07M | 61.8M |
Total Assets | 519.27M▲ 0% | 554.46M▲ 6.8% | 516.93M▼ 6.8% | 640.89M▲ 24.0% | 577.74M▼ 9.9% | 596.55M▲ 3.3% | 632.76M▲ 6.1% | 748.19M▲ 18.2% | 742.91M▼ 0.7% |
Asset Turnover | 2.02x | 2.14x | 2.05x | 1.77x | 2.05x | 1.67x | 1.46x | 1.14x | 1.25x |
Asset Growth % | 10.33% | 6.78% | -6.77% | 23.98% | -9.85% | 3.26% | 6.07% | 18.24% | -0.71% |
Total Current Liabilities | 141.18M | 148.69M | 136.1M | 168.07M | 160.79M | 143.83M | 118.84M | 139.63M | 128.56M |
Accounts Payable | 11.79M | 9.95M | 12.53M | 18.2M | 13.51M | 11.05M | 10.07M | 11.98M | 17.26M |
Days Payables Outstanding | 22.02 | 16.7 | 22.63 | 29.8 | 21.35 | 19.46 | 19.41 | 24.89 | 31.37 |
Short-Term Debt | 0 | 0 | 8.32M | 8.62M | 7.08M | 6.89M | 786K | 23M | 14M |
Deferred Revenue (Current) | 17M | 15.05M | 13.85M | 15.95M | 19.64M | 20.88M | 13.91M | 12.05M | 0 |
Other Current Liabilities | 28.71M | 35.69M | 68.96M | 85.36M | 83.01M | 82.71M | 73.75M | -4.75M | 97.3M |
Current Ratio | 2.41x | 2.64x | 2.41x | 2.52x | 2.26x | 2.65x | 3.52x | 2.00x | 2.24x |
Quick Ratio | 1.96x | 2.09x | 1.90x | 1.98x | 1.65x | 2.18x | 3.00x | 1.50x | 1.45x |
Cash Conversion Cycle | 100.22 | 125.17 | 104.87 | 120.36 | 136.25 | 101.32 | 101.88 | 123.45 | - |
Total Non-Current Liabilities | 14.88M | 14.63M | 29.12M | 31.16M | 21.83M | 18.24M | 16.71M | 22.24M | 28.08M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 17.27M | 12.86M | 10.21M | 6.89M | 5.14M | 10.19M | 0 |
Deferred Tax Liabilities | 13.73M | 13.37M | 10.28M | 12.01M | 7.5M | 4.07M | 4.55M | 4.07M | 4.89M |
Other Non-Current Liabilities | 1.15M | 1.26M | 1.57M | 6.3M | 4.11M | 7.28M | 7.02M | 7.97M | 23.19M |
Total Liabilities | 156.06M | 163.32M | 165.22M | 199.24M | 182.62M | 162.08M | 135.56M | 161.86M | 156.64M |
Total Debt | 0 | 0 | 25.6M | 21.47M | 17.3M | 13.78M | 13.21M | 39.2M | 14M |
Net Debt | -247.13M | -214.33M | -209.23M | -291.4M | -222.54M | -274.64M | -317.21M | -142.56M | -144.38M |
Debt / Equity | - | - | 0.07x | 0.05x | 0.04x | 0.03x | 0.03x | 0.07x | 0.02x |
Debt / EBITDA | - | - | 0.15x | 0.11x | 0.09x | 0.11x | 0.12x | 0.44x | 0.15x |
Net Debt / EBITDA | -1.66x | -1.05x | -1.24x | -1.46x | -1.16x | -2.13x | -2.80x | -1.61x | -1.59x |
Interest Coverage | 2927.96x | 5320.72x | 2215.00x | 351.98x | 2994.72x | 566.73x | 392.04x | 272.71x | 50.32x |
Total Equity | 363.21M▲ 0% | 391.15M▲ 7.7% | 351.71M▼ 10.1% | 441.65M▲ 25.6% | 395.12M▼ 10.5% | 434.47M▲ 10.0% | 497.2M▲ 14.4% | 586.33M▲ 17.9% | 586.27M▼ 0.0% |
Equity Growth % | 11.66% | 7.69% | -10.08% | 25.57% | -10.53% | 9.96% | 14.44% | 17.93% | -0.01% |
Book Value per Share | 14.70 | 15.87 | 15.41 | 20.78 | 19.42 | 22.50 | 25.70 | 30.60 | 31.56 |
Total Shareholders' Equity | 363.21M | 391.15M | 351.71M | 441.65M | 395.12M | 434.47M | 497.2M | 532.11M | 533.1M |
Common Stock | 24K | 24K | 22K | 21K | 19K | 19K | 19K | 19K | 18K |
Retained Earnings | 288.07M | 329.5M | 306.15M | 382.79M | 344.64M | 391.64M | 445.22M | 478.94M | 465.72M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.43M | -10.39M | -13.9M | -3.63M | 458K | -12.79M | -13.7M | -22.67M | -16.18M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 54.22M | 53.17M |
USNA Cash Flow Statement
USANA Health Sciences, Inc. (USNA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Jan'26 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 123.78M | 152.12M | 126.73M | 160.4M | 121.23M | 103.9M | 70.64M | 60.99M | 22.35M |
Operating CF Margin % | 11.82% | 12.79% | 11.95% | 14.14% | 10.22% | 10.4% | 7.67% | 7.14% | 2.42% |
Operating CF Growth % | -9.67% | 22.89% | -16.69% | 26.57% | -24.42% | -14.29% | -32.01% | -13.66% | -63.36% |
Net Income | 62.53M | 126.22M | 100.53M | 124.66M | 116.5M | 69.35M | 63.79M | 42.06M | 10.76M |
Depreciation & Amortization | 16.11M | 16.84M | 23.01M | 22.51M | 22.19M | 21.41M | 20.39M | 22.23M | 32.56M |
Stock-Based Compensation | 15.48M | 14.96M | 15.54M | 14.39M | 14.3M | 13.48M | 14.6M | 14.56M | 13.83M |
Deferred Taxes | 19.31M | 699K | -3.63M | -2.42M | -2.97M | -7.18M | -2.75M | -6.74M | -7.13M |
Other Non-Cash Items | 2.75M | 1.15M | 84K | 701K | 61K | 6.07M | 2.61M | 1.89M | 15.41M |
Working Capital Changes | 7.6M | -7.75M | -8.79M | 556K | -28.86M | 771K | -28M | -13M | -43.08M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 6.05M | -23.1M | 12.99M | -16.78M | -10.5M | 15.8M | 2.35M | -2.12M | -34.69M |
Change in Payables | 3.04M | -1.72M | 1.83M | 6.08M | -4.57M | -2.66M | -428K | -1.27M | 5.2M |
Cash from Investing | -12.9M | -69M | 47.49M | -33.96M | -14.19M | -12.37M | -11.97M | -213.09M | -10.13M |
Capital Expenditures | -13.22M | -11.43M | -16.57M | -15.09M | -12.76M | -10.4M | -14.49M | -10.07M | -13.82M |
CapEx % of Revenue | 1.26% | 0.96% | 1.56% | 1.33% | 1.08% | 1.04% | 1.57% | 1.18% | 1.49% |
Acquisitions | 22K | 381K | 17K | 6K | -1.94M | -6.53M | 0 | -203.34M | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 318K | 4.85M | 231K | 281K | 131K | 7K | 15K | 64K | 3.7M |
Cash from Financing | -50.32M | -105.28M | -152.05M | -59.44M | -181.41M | -30.09M | -14.24M | 9.55M | -40.6M |
Debt Issued (Net) | 0 | 0 | -65K | -46K | 0 | 0 | 792K | 22.22M | -9M |
Equity Issued (Net) | -50M | -105.38M | -151.99M | -57.03M | -177.84M | -25.38M | -11.6M | -9.44M | -27.51M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -50M | -105.38M | -150M | -57.03M | -177.84M | -25.38M | -11.6M | -9.44M | -27.51M |
Other Financing | -316K | 98K | 0 | -2.37M | -3.58M | -4.71M | -3.43M | -3.22M | -4.1M |
Net Change in Cash | 71.36M▲ 0% | -33.3M▼ 146.7% | 20.45M▲ 161.4% | 78.25M▲ 282.6% | -72.28M▼ 192.4% | 47.67M▲ 165.9% | 41.93M▼ 12.0% | -148.74M▼ 454.8% | -23.27M▲ 84.4% |
Free Cash Flow | 110.56M▲ 0% | 140.69M▲ 27.2% | 110.16M▼ 21.7% | 145.31M▲ 31.9% | 108.46M▼ 25.4% | 93.5M▼ 13.8% | 56.15M▼ 40.0% | 50.92M▼ 9.3% | 8.53M▼ 83.3% |
FCF Margin % | 10.56% | 11.83% | 10.38% | 12.81% | 9.14% | 9.36% | 6.1% | 5.96% | 0.92% |
FCF Growth % | 5.97% | 27.25% | -21.7% | 31.9% | -25.36% | -13.79% | -39.95% | -9.31% | -83.26% |
FCF per Share | 4.47 | 5.71 | 4.83 | 6.84 | 5.33 | 4.84 | 2.90 | 2.66 | 0.46 |
FCF Conversion (FCF/Net Income) | 1.98x | 1.21x | 1.26x | 1.29x | 1.04x | 1.50x | 1.11x | 1.45x | 2.08x |
Interest Paid | 16K | 6K | 11K | 711K | 10K | 49K | 68K | 76K | 0 |
Taxes Paid | 46.01M | 70.68M | 54.91M | 53.02M | 59.52M | 45.86M | 44.25M | 40.47M | 0 |
USNA Key Ratios
USANA Health Sciences, Inc. (USNA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 33.01% | 18.17% | 33.47% | 27.06% | 31.43% | 27.85% | 16.72% | 13.69% | 7.76% | 1.84% |
Return on Invested Capital (ROIC) | 72.41% | 74.84% | 96.46% | 68.68% | 90.44% | 79.08% | 48.56% | 41.08% | 15.95% | 8.61% |
Gross Margin | 80.75% | 81.35% | 81.72% | 80.96% | 80.36% | 80.54% | 79.24% | 79.44% | 79.43% | 78.29% |
Net Margin | 9.94% | 5.97% | 10.61% | 9.48% | 10.99% | 9.82% | 6.94% | 6.93% | 4.92% | 1.16% |
Debt / Equity | - | - | - | 0.07x | 0.05x | 0.04x | 0.03x | 0.03x | 0.07x | 0.02x |
Interest Coverage | 312.21x | 2927.96x | 5320.72x | 2215.00x | 351.98x | 2994.72x | 566.73x | 392.04x | 272.71x | 50.32x |
FCF Conversion | 1.37x | 1.98x | 1.21x | 1.26x | 1.29x | 1.04x | 1.50x | 1.11x | 1.45x | 2.08x |
Revenue Growth | 9.54% | 4.09% | 13.56% | -10.79% | 6.95% | 4.57% | -15.83% | -7.77% | -7.22% | 8.28% |
Related:USNA Dividend History·USNA Revenue History·USNA Price History·USNA P/E History·USNA Financial Ratios·USNA Institutional Holders
USNA SEC Filings & Documents
USANA Health Sciences, Inc. (USNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
USNA Frequently Asked Questions
USANA Health Sciences, Inc. (USNA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
USANA Health Sciences, Inc. (USNA) reported $925.3M in revenue for fiscal year 2025. This represents a 1532% increase from $56.7M in 1996.
USANA Health Sciences, Inc. (USNA) grew revenue by 8.3% over the past year. This is steady growth.
Yes, USANA Health Sciences, Inc. (USNA) is profitable, generating $10.8M in net income for fiscal year 2025 (1.2% net margin).
Dividend & Returns
USANA Health Sciences, Inc. (USNA) has a return on equity (ROE) of 1.8%. This is below average, suggesting room for improvement.
USANA Health Sciences, Inc. (USNA) generated $8.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.